Aratana Therapeutics Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$238M
- Investors
-
1
Aratana Therapeutics General Information
Description
Developer of biopharmaceutical technology designed for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics and consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.
Contact Information
Website
www.aratana.comCorporate Office
- 11400 Tomahawk Creek Parkway
- Suite 340
- Leawood, KS 66211
- United States
Corporate Office
- 11400 Tomahawk Creek Parkway
- Suite 340
- Leawood, KS 66211
- United States
Aratana Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 18-Jul-2019 | $238M | Completed | Generating Revenue | ||
| 11. Secondary Transaction - Open Market | 28-Apr-2016 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Open Market | 29-Apr-2014 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Stock Distribution | 03-Mar-2014 | Completed | Generating Revenue | |||
| 8. 2PO | 31-Jan-2014 | Completed | Generating Revenue | |||
| 7. IPO | 27-Jun-2013 | Completed | Generating Revenue | |||
| 6. Debt - General | 07-Mar-2013 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 31-Jan-2013 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 06-Dec-2011 | $15.5M | $35.5M | Completed | Product Development | |
| 3. Early Stage VC (Series A1) | 07-Jan-2011 | $10M | $20M | Completed | Product Development |
Aratana Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 2,750,000 | $0.001000 | 8% | $2 | $2 | 1x | $2 | 10.99% |
| Series A | 10,000,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 39.97% |
Aratana Therapeutics Comparisons
Industry
Financing
Details
Aratana Therapeutics Competitors (1)
One of Aratana Therapeutics’s competitors is Immucell, a Corporation company based in Portland, ME.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immucell | Corporation | Portland, ME |
Aratana Therapeutics Patents
Aratana Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016211520-A1 | Compositions and methods for chronic use of a weight-gaining compound | Active | 28-Jan-2015 | ||
| AU-2016211520-B2 | Compositions and methods for chronic use of a weight-gaining compound | Active | 28-Jan-2015 | ||
| CA-2974012-A1 | Compositions and methods for chronic use of a weight-gaining compound | Active | 28-Jan-2015 | ||
| CA-2974012-C | Compositions and methods for chronic use of a weight-gaining compound | Active | 28-Jan-2015 | ||
| US-10064909-B2 | Compositions and methods for chronic use of a weight-gaining compound | Active | 28-Jan-2015 | A61K38/05 |
Aratana Therapeutics Signals
Aratana Therapeutics Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avalon Ventures | Venture Capital | Minority | ||
| Ewing Marion Kauffman Foundation | Limited Partner | Minority | ||
| Grassmere Partners | PE/Buyout | Minority | ||
| Kansas Bioscience Authority | Government | Minority | ||
| MPM BioImpact | Venture Capital | Minority |
Aratana Therapeutics Investments & Acquisitions (3)
Aratana Therapeutics’s most recent deal was a Early Stage VC with ViroVet for . The deal was made on 09-Oct-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ViroVet | 09-Oct-2017 | Early Stage VC | Other Agriculture | ||
| Okapi Sciences | 06-Jan-2014 | Merger/Acquisition | Drug Delivery | ||
| Vet Therapeutics | 16-Oct-2013 | Merger/Acquisition | Other Commercial Services |
Aratana Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.35 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Aratana Therapeutics FAQs
-
When was Aratana Therapeutics founded?
Aratana Therapeutics was founded in 2010.
-
Where is Aratana Therapeutics headquartered?
Aratana Therapeutics is headquartered in Leawood, KS.
-
What is the size of Aratana Therapeutics?
Aratana Therapeutics has 17 total employees.
-
What industry is Aratana Therapeutics in?
Aratana Therapeutics’s primary industry is Other Commercial Products.
-
Is Aratana Therapeutics a private or public company?
Aratana Therapeutics is a Private company.
-
What is the current valuation of Aratana Therapeutics?
The current valuation of Aratana Therapeutics is .
-
What is Aratana Therapeutics’s current revenue?
The current revenue for Aratana Therapeutics is .
-
How much funding has Aratana Therapeutics raised over time?
Aratana Therapeutics has raised $179M.
-
Who are Aratana Therapeutics’s investors?
Avalon Ventures, Ewing Marion Kauffman Foundation, Grassmere Partners, Kansas Bioscience Authority, and MPM BioImpact are 5 of 11 investors who have invested in Aratana Therapeutics.
-
Who are Aratana Therapeutics’s competitors?
Immucell is a competitor of Aratana Therapeutics.
-
When was Aratana Therapeutics acquired?
Aratana Therapeutics was acquired on 18-Jul-2019.
-
Who acquired Aratana Therapeutics?
Aratana Therapeutics was acquired by Elanco Animal Health.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process